Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer

Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1987-02, Vol.294 (6570), p.467-469
Main Authors: Cantwell, B M, Harris, A L
Format: Article
Language:English
Subjects:
Adult
Aged
Breast cancer
Calcium
Clinical Research
Corticosteroids
Diphosphonates
Diphosphonates - therapeutic use
Dosage
Female
Humans
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Intravenous infusions
Lung neoplasms
Male
Middle Aged
Neoplasms - complications
Oncology
Oral rehydration
Pamidronate
Serum albumins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3
cites cdi_FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3
container_end_page 469
container_issue 6570
container_start_page 467
container_title BMJ
container_volume 294
creator Cantwell, B M
Harris, A L
description Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The serum calcium concentrations decreased significantly after treatment with aminohydroxypropylidene diphosphonate. Ten patients became normocalcaemic (normal range, adjusted for serum albumin, 2.25-2.75 mmol/l), two became hypocalcaemic, three showed decreases in serum calcium concentrations of more than 0.75 mmol/l, and one showed a decrease of more than 0.55 mmol/l. Only one patient had a minimum concentration greater than 2.77 mmol/l. Aminohydroxypropylidene diphosphonate was effective in metastatic and non-metastatic hypercalcaemia, and its hypocalcaemic effect was prolonged in some cases. There were no appreciable side effects. Single high dose infusions of aminohydroxypropylidene diphosphonate could replace conventional daily lower dose infusions, but the optimum frequency of high dose infusions remains to be determined.
doi_str_mv 10.1136/bmj.294.6570.467
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1245518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>29526120</jstor_id><sourcerecordid>29526120</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3</originalsourceid><addsrcrecordid>eNqFkduL1DAUxoMo67Duuy9CQPBFOubWpH0RZFhvLIqo-xrSNJlmbJOatLL9702ZYby87EM4B37f-TgnHwBPMdpiTPmrZjhsSc22vBRoy7h4ADaY8aooK0ofgg0iXBSIE_oYXKV0QAgRKqqaswtwQTGigqINGK-tNXqCwcLk_L43sHP7DrYhGei8nZMLPq1UDc6HbmljuFvGGMald63xBrZu7ELKz6vJwOBht4wmatVrZQanoFZzMi1sltx5beIT8MiqPpmrU70E399ef9u9L24-v_uwe3NTNIxjUVhGGi5QLaoG6VrQSmFsGMOVrkjZIKpsxYSxuaLWCsyRZaLOHRLKKttoegleH33HuRlMq42fourlGN2g4iKDcvJf4l0n9-GXxISVJa6ywYuTQQw_Z5MmObikTd8rb8KcpBCM5hTuF2ImKBElzcLn_wkPYY4-_4LEQvB8N69XO3RU6RhSisaed8ZIrrnLnLvMucs1d5lzzyPP_r71PHBK-Q8_pCnEMyZ1STgmKy-O3KXJ3J25ij9kdhel_HS7k1_41487fktkmfUvj_p1k3u3-w0e0NGP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776461698</pqid></control><display><type>article</type><title>Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>BMJ Publishing</source><source>PubMed</source><creator>Cantwell, B M ; Harris, A L</creator><creatorcontrib>Cantwell, B M ; Harris, A L</creatorcontrib><description>Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The serum calcium concentrations decreased significantly after treatment with aminohydroxypropylidene diphosphonate. Ten patients became normocalcaemic (normal range, adjusted for serum albumin, 2.25-2.75 mmol/l), two became hypocalcaemic, three showed decreases in serum calcium concentrations of more than 0.75 mmol/l, and one showed a decrease of more than 0.55 mmol/l. Only one patient had a minimum concentration greater than 2.77 mmol/l. Aminohydroxypropylidene diphosphonate was effective in metastatic and non-metastatic hypercalcaemia, and its hypocalcaemic effect was prolonged in some cases. There were no appreciable side effects. Single high dose infusions of aminohydroxypropylidene diphosphonate could replace conventional daily lower dose infusions, but the optimum frequency of high dose infusions remains to be determined.</description><identifier>ISSN: 0267-0623</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.294.6570.467</identifier><identifier>PMID: 3103730</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adult ; Aged ; Breast cancer ; Calcium ; Clinical Research ; Corticosteroids ; Diphosphonates ; Diphosphonates - therapeutic use ; Dosage ; Female ; Humans ; Hypercalcemia - drug therapy ; Hypercalcemia - etiology ; Intravenous infusions ; Lung neoplasms ; Male ; Middle Aged ; Neoplasms - complications ; Oncology ; Oral rehydration ; Pamidronate ; Serum albumins</subject><ispartof>BMJ, 1987-02, Vol.294 (6570), p.467-469</ispartof><rights>Copyright 1987 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Feb 21, 1987</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3</citedby><cites>FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/29526120$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/29526120$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3192,27922,27923,53789,53791,58236,58469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3103730$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cantwell, B M</creatorcontrib><creatorcontrib>Harris, A L</creatorcontrib><title>Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer</title><title>BMJ</title><addtitle>Br Med J (Clin Res Ed)</addtitle><description>Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The serum calcium concentrations decreased significantly after treatment with aminohydroxypropylidene diphosphonate. Ten patients became normocalcaemic (normal range, adjusted for serum albumin, 2.25-2.75 mmol/l), two became hypocalcaemic, three showed decreases in serum calcium concentrations of more than 0.75 mmol/l, and one showed a decrease of more than 0.55 mmol/l. Only one patient had a minimum concentration greater than 2.77 mmol/l. Aminohydroxypropylidene diphosphonate was effective in metastatic and non-metastatic hypercalcaemia, and its hypocalcaemic effect was prolonged in some cases. There were no appreciable side effects. Single high dose infusions of aminohydroxypropylidene diphosphonate could replace conventional daily lower dose infusions, but the optimum frequency of high dose infusions remains to be determined.</description><subject>Adult</subject><subject>Aged</subject><subject>Breast cancer</subject><subject>Calcium</subject><subject>Clinical Research</subject><subject>Corticosteroids</subject><subject>Diphosphonates</subject><subject>Diphosphonates - therapeutic use</subject><subject>Dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Hypercalcemia - drug therapy</subject><subject>Hypercalcemia - etiology</subject><subject>Intravenous infusions</subject><subject>Lung neoplasms</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - complications</subject><subject>Oncology</subject><subject>Oral rehydration</subject><subject>Pamidronate</subject><subject>Serum albumins</subject><issn>0267-0623</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><recordid>eNqFkduL1DAUxoMo67Duuy9CQPBFOubWpH0RZFhvLIqo-xrSNJlmbJOatLL9702ZYby87EM4B37f-TgnHwBPMdpiTPmrZjhsSc22vBRoy7h4ADaY8aooK0ofgg0iXBSIE_oYXKV0QAgRKqqaswtwQTGigqINGK-tNXqCwcLk_L43sHP7DrYhGei8nZMLPq1UDc6HbmljuFvGGMald63xBrZu7ELKz6vJwOBht4wmatVrZQanoFZzMi1sltx5beIT8MiqPpmrU70E399ef9u9L24-v_uwe3NTNIxjUVhGGi5QLaoG6VrQSmFsGMOVrkjZIKpsxYSxuaLWCsyRZaLOHRLKKttoegleH33HuRlMq42fourlGN2g4iKDcvJf4l0n9-GXxISVJa6ywYuTQQw_Z5MmObikTd8rb8KcpBCM5hTuF2ImKBElzcLn_wkPYY4-_4LEQvB8N69XO3RU6RhSisaed8ZIrrnLnLvMucs1d5lzzyPP_r71PHBK-Q8_pCnEMyZ1STgmKy-O3KXJ3J25ij9kdhel_HS7k1_41487fktkmfUvj_p1k3u3-w0e0NGP</recordid><startdate>19870221</startdate><enddate>19870221</enddate><creator>Cantwell, B M</creator><creator>Harris, A L</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19870221</creationdate><title>Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer</title><author>Cantwell, B M ; Harris, A L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Breast cancer</topic><topic>Calcium</topic><topic>Clinical Research</topic><topic>Corticosteroids</topic><topic>Diphosphonates</topic><topic>Diphosphonates - therapeutic use</topic><topic>Dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Hypercalcemia - drug therapy</topic><topic>Hypercalcemia - etiology</topic><topic>Intravenous infusions</topic><topic>Lung neoplasms</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - complications</topic><topic>Oncology</topic><topic>Oral rehydration</topic><topic>Pamidronate</topic><topic>Serum albumins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cantwell, B M</creatorcontrib><creatorcontrib>Harris, A L</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>ProQuest Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cantwell, B M</au><au>Harris, A L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J (Clin Res Ed)</addtitle><date>1987-02-21</date><risdate>1987</risdate><volume>294</volume><issue>6570</issue><spage>467</spage><epage>469</epage><pages>467-469</pages><issn>0267-0623</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>Single intravenous infusions of 30 mg aminohydroxypropylidene diphosphonate were given to 16 patients who had malignant hypercalcaemia to assess host tolerance and the effect on serum calcium concentration. Ten of these patients also received intravenous rehydration or corticosteroids, or both. The serum calcium concentrations decreased significantly after treatment with aminohydroxypropylidene diphosphonate. Ten patients became normocalcaemic (normal range, adjusted for serum albumin, 2.25-2.75 mmol/l), two became hypocalcaemic, three showed decreases in serum calcium concentrations of more than 0.75 mmol/l, and one showed a decrease of more than 0.55 mmol/l. Only one patient had a minimum concentration greater than 2.77 mmol/l. Aminohydroxypropylidene diphosphonate was effective in metastatic and non-metastatic hypercalcaemia, and its hypocalcaemic effect was prolonged in some cases. There were no appreciable side effects. Single high dose infusions of aminohydroxypropylidene diphosphonate could replace conventional daily lower dose infusions, but the optimum frequency of high dose infusions remains to be determined.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>3103730</pmid><doi>10.1136/bmj.294.6570.467</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0267-0623
ispartof BMJ, 1987-02, Vol.294 (6570), p.467-469
issn 0267-0623
0959-8138
1468-5833
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1245518
source JSTOR Archival Journals and Primary Sources Collection; BMJ Publishing; PubMed
subjects Adult
Aged
Breast cancer
Calcium
Clinical Research
Corticosteroids
Diphosphonates
Diphosphonates - therapeutic use
Dosage
Female
Humans
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Intravenous infusions
Lung neoplasms
Male
Middle Aged
Neoplasms - complications
Oncology
Oral rehydration
Pamidronate
Serum albumins
title Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T02%3A25%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20single%20high%20dose%20infusions%20of%20aminohydroxypropylidene%20diphosphonate%20on%20hypercalcaemia%20caused%20by%20cancer&rft.jtitle=BMJ&rft.au=Cantwell,%20B%20M&rft.date=1987-02-21&rft.volume=294&rft.issue=6570&rft.spage=467&rft.epage=469&rft.pages=467-469&rft.issn=0267-0623&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.294.6570.467&rft_dat=%3Cjstor_pubme%3E29526120%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b4617-f42b670978b0c9738a11e4418c825b03af847ef3af0df7160f479df707afafbc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1776461698&rft_id=info:pmid/3103730&rft_jstor_id=29526120&rfr_iscdi=true